Evidence map›Paper›PMID 41592680›Full record

ArticleJournal of advanced research2026

Targeted delivery of senolytic drugs using macrophage membrane-camouflaged magnetic nanoparticles inhibits endplate sclerosis.

Weiping Su, Chenhao Shi, Yixiao Pan, Boyan Ma, Yueke Sun, Mingzhe Fan, Lantian Zhao, Yuanyang Zhu, Xianglong Zhuo, Shiqing Feng and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of advanced research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Weiping SuDepartment of Spine Surgery, The Second Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan 250000, China; Department of Orthopedics, The Third Xiangya Hospital, Central South University, Changsha 410013, China; Department of Orthopedics, The Second Xiangya Hospital, Central South University, Changsha 410013, China.
Chenhao ShiDepartment of Spine Surgery, The Second Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan 250000, China; Department of Orthopedics, The First-affiliated Hospital, Zhengzhou University, Zhengzhou 450000, China.
Yixiao PanDepartment of Spine Surgery, The Second Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan 250000, China; Department of Orthopedics, The Third Xiangya Hospital, Central South University, Changsha 410013, China; Postdoctoral Station of Pharmacy, the Third Xiangya Hospital, Central South University, Changsha 410013, China.
Boyan MaDepartment of Spine Surgery, The Second Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan 250000, China; Department of Orthopedics, The Third Xiangya Hospital, Central South University, Changsha 410013, China.
Yueke SunDepartment of Spine Surgery, The Second Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan 250000, China; Department of Orthopedics, The First-affiliated Hospital, Zhengzhou University, Zhengzhou 450000, China.
Mingzhe FanDepartment of Spine Surgery, The Second Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan 250000, China; Department of Orthopedics, The First-affiliated Hospital, Zhengzhou University, Zhengzhou 450000, China.
Lantian ZhaoDepartment of Spine Surgery, The Second Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan 250000, China; Department of Orthopedics, The First-affiliated Hospital, Zhengzhou University, Zhengzhou 450000, China.
Yuanyang ZhuDepartment of Spine Surgery, The Second Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan 250000, China; Department of Orthopedics, The First-affiliated Hospital, Zhengzhou University, Zhengzhou 450000, China.
Xianglong ZhuoDepartment of Spine Surgery, The Second Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan 250000, China. Electronic address: doctorzhuo@139.com.
Shiqing FengDepartment of Spine Surgery, The Second Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan 250000, China. Electronic address: shiqingfeng@sdu.edu.cn.
Shuangfei NiDepartment of Spine Surgery, The Second Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan 250000, China; Department of Orthopedics, The First-affiliated Hospital, Zhengzhou University, Zhengzhou 450000, China. Electronic address: nishuangfei@yeah.net.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionLow back pain (LBP) is a prevalent cause of disability worldwide. A crucial mechanism underlying LBP is that senescent-like macrophages induce endplate sclerosis by coupling angiogenesis-osteogenesis through IL-10. Then, the osteoclasts attract sensory innervation to perceive pain during endplate sclerosis. Therefore, targeted clearance of senescent-like macrophages is expected to be a new direction for LBP treatment.

objectivesIn light of the side effects of systemic application of senolytic drugs, we propose to construct a targeted drug delivery system to accurately remove senescent-like macrophages in degenerating endplates.

methodsIn this study, iron oxide nanoparticles (Fe

resultsIn vivo and in vitro findings showed that senescent-like macrophages were effectively eliminated by MM@MS@ABT, thereby inhibiting the expression and secretion of IL-10 from senescent-like macrophages. This reduced CD31

conclusionTogether, MM@MS@ABT exhibits a dual-targeting ability to aggregate near degenerated endplates and release senolytic drugs precisely to eliminate senescent-like macrophages in the endplates of LSI mice. It represents a potentially effective strategy for the treatment of LBP.

Indexed as

Aniline CompoundsDrug Delivery SystemsMacrophagesMagnetite NanoparticlesAnimalsHumansMaleMiceMice, Inbred C57BLSclerosisAniline CompoundsMagnetite NanoparticlesEndplate sclerosisMacrophage membraneMagnetic nanoparticlesSenolytic drugs

Identifiers

PMID41592680
PMCPMC13669599

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.